Immunoglobulin G4-kappa

Immunoglobulin G4-kappa Uses, Dosage, Side Effects, Food Interaction and all others data.

Immunoglobulin G4-kappa is under investigation in clinical trial NCT02953782 (Trial of Immunoglobulin G4-kappa (Hu5f9-g4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer).

Trade Name	Immunoglobulin G4-kappa
Generic	Magrolimab
Magrolimab Other Names	Anti-cd47 monoclonal antibody hu5f9-g4, Immunoglobulin g4-kappa, anti-(homo sapiens cd47 (integrin associated protein, iap, mer6, oa3)), monoclonal antibodygamma4 heavy chain (1-444) (vh (homo sapiens ighv1-3*01 (87.8%)-(ighd)-ighj4*01 (100%)) (8.8.10) (1-117)-homo sapiens ighg4*01 (ch1 (118-2, Immunoglobulin g4(225-proline), anti-(human cd47 antigen) (human-mus musculus monoclonal hu5f9-g4 .gamma.4-chain), disulfide with human-mus musculus monoclonal hu5f9-g4 .kappa.-chain, dimer, Magrolimab
Type
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Innovators Monograph

You find simplified version here Immunoglobulin G4-kappa